Baseline Susceptibility of Primary HIV-2 to Entry Inhibitors

BACKGROUND: The baseline susceptibility of primary HIV-2 to maraviroc (MVC) and other entry inhibitors is currently unknown. METHODS: The susceptibility of 19 HIV-2 isolates obtained from asymptomatic and AIDS patients and seven HIV-1 clinical isolates to the fusion inhibitors enfuvirtide (ENF) and...

Full description

Bibliographic Details
Main Author: Borrego, P (author)
Other Authors: Calado, R (author), Marcelino, JM (author), Bártolo, I (author), Rocha, C (author), Cavaco-Silva, P (author), Doroana, M (author), Antunes, F (author), Maltez, F (author), Caixas, U (author), Barroso, H (author), Taveira, N (author)
Format: article
Language:eng
Published: 2016
Subjects:
HSJ MED
HCC INF
Amides/pharmacology
Amides/therapeutic use
Anti-HIV Agents/pharmacology
Anti-HIV Agents/therapeutic use
CCR5 Receptor Antagonists
Cyclohexanes/pharmacology
Cyclohexanes/therapeutic use
HIV Envelope Protein gp41/pharmacology
HIV Envelope Protein gp41/therapeutic use
HIV Fusion Inhibitors/pharmacology
HIV Fusion Inhibitors/therapeutic use
HIV Infections/drug therapy
HIV Infections/virology
HIV-1/drug effects
HIV-2/drug effects
Inhibitory Concentration 50
Microbial Sensitivity Tests
Peptide Fragments/pharmacology
Peptide Fragments/therapeutic use
Quaternary Ammonium Compounds/pharmacology
Quaternary Ammonium Compounds/therapeutic use
Triazoles/pharmacology
Triazoles/therapeutic use
Online Access:http://hdl.handle.net/10400.17/2417
Country:Portugal
Oai:oai:repositorio.chlc.min-saude.pt:10400.17/2417

Internet

http://hdl.handle.net/10400.17/2417

Similar Items